Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professors Stephanie Dakin and Paul Bowness have been announced as 2021 recipients of the Novartis Institutes for BioMedical Research (NIBR) Global Scholars Program (NGSP).

Professors Steph Dakin and Paul Bowness

NGSP is a competitive program designed for innovators from invited institutions to gain funding for breakthrough science that will advance Novartis' mission to improve and extend peoples' lives.

Stephanie Dakin, Associate Professor of Musculoskeletal Sciences at NDORMS joined NGSP to further her research into tendinopathy. She said: "I am delighted and honoured to be recognised as a recipient of the NIBR Global Scholars Program and look forward to establishing a fruitful collaboration with Novartis. This strong collaborative link between academia and pharma provides a unique opportunity to catalyse the development of new therapeutic strategies for tendinopathy treatment."

Paul Bowness, Professor of Experimental Rheumatology will be using his time on the NGSP to focus on finding new ways to understand and treat Spondyloarthritis. "I am excited and honoured to be one of the recipients of 2021 NIBR Global Scholars Program," said Paul. "In collaboration both with Dr Liye Chen at NDORMS and the team at Novartis, we will investigate the scientific mechanisms and therapeutic potential of novel approaches in Spondyloarthritis, a common group of arthritic diseases affecting young people all over the world."

Stephanie and Paul were among five recipients of the program in 2021 and, together with Novartis, they will explore new scientific frontiers in drug discovery and/or clinical research to improve the lives of patients.

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.